A STUDY OF GENE THERAPY FOR CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH)
- This study is designed to evaluate the safety, tolerability, and efficacy of AAV5-based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.
- Sponsor: Adrenas Therapeutics
- Contact Person: Patient Advocacy; email ClinicalTrials@AdrenasTx.com
- Who should consider participation: If you are an adult living with classic CAH due to 21-hydroxylase deficiency and interested in gene therapy treatment that may correct hormone imbalances.
- https://clinicaltrials.gov/study/NCT05101902